Evidence map›Paper›PMID 36840015›Full record

ReviewPharmaceutics2023

Therapeutic Potential of Dopamine and Related Drugs as Anti-Inflammatories and Antioxidants in Neuronal and Non-Neuronal Pathologies.

Cindy Bandala, Noemi Cárdenas-Rodríguez, Julieta Griselda Mendoza-Torreblanca, Itzel Jatziri Contreras-García, Valentín Martínez-López, Teresita Rocio Cruz-Hernández, Jazmín Carro-Rodríguez, Marco Antonio Vargas-Hernández, Iván Ignacio-Mejía, Alfonso Alfaro-Rodriguez and 1 more

Open access · goldAbstract readReview
In one paragraph

Review in Pharmaceutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 21 citations in OpenAlex.

  1. Tumor-Targeting TACS omega · 2025
    Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 7 institutions in 1 country.

Cindy BandalaNeurociencia Básica, Instituto Nacional de Rehabilitación LGII, Secretaría de Salud, Mexico City 14389, Mexico.ORCID 0000-0002-7414-2621
Noemi Cárdenas-RodríguezEscuela Superior de Medicina, Instituto Politécnico Nacional, Mexico City 11340, Mexico.
Julieta Griselda Mendoza-TorreblancaLaboratorio de Neurociencias, Subdirección de Medicina Experimental, Instituto Nacional de Pediatría, Mexico City 04530, Mexico.ORCID 0000-0003-0702-5318
Itzel Jatziri Contreras-GarcíaLaboratorio de Fisiología, Escuela Militar de Graduados de Sanidad, UDEFA, Mexico City 11200, Mexico.
Valentín Martínez-LópezUnidad de Ingeniería de Tejidos, Terapia Celular y Medicina Regenerativa, Instituto Nacional de Rehabilitación Luis Guillermo Ibarra Ibarra, Mexico City 14389, Mexico.
Teresita Rocio Cruz-HernándezEscuela Superior de Medicina, Instituto Politécnico Nacional, Mexico City 11340, Mexico.
Jazmín Carro-RodríguezEscuela de Biología Experimental, Unidad Iztapalapa, Universidad Autónoma Metropolitana, Mexico City 09340, Mexico.
Marco Antonio Vargas-HernándezSubdirección de Investigación, Escuela Militar de Graduados de Sanidad, Mexico City 11200, Mexico.
Iván Ignacio-MejíaLaboratorio de Medicina Traslacional, Escuela Militar de Graduados de Sanidad, Mexico City 11200, Mexico.ORCID 0000-0003-3792-4613
Alfonso Alfaro-RodriguezNeurociencia Básica, Instituto Nacional de Rehabilitación LGII, Secretaría de Salud, Mexico City 14389, Mexico.
Eleazar Lara-PadillaEscuela Superior de Medicina, Instituto Politécnico Nacional, Mexico City 11340, Mexico.
Hospital Central Militar · MXInstituto Nacional de Pediatria · MXInstituto Politécnico Nacional · MXSecretaria de Salud · MXInstituto Nacional de Rehabilitación · MXUniversidad Autónoma Metropolitana · MXUniversidad del Ejército y Fuerza Aérea · MX

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Dopamine (DA), its derivatives, and dopaminergic drugs are compounds widely used in the management of diseases related to the nervous system. However, DA receptors have been identified in nonneuronal tissues, which has been related to their therapeutic potential in pathologies such as sepsis or septic shock, blood pressure, renal failure, diabetes, and obesity, among others. In addition, DA and dopaminergic drugs have shown anti-inflammatory and antioxidant properties in different kinds of cells.

aimTo compile the mechanism of action of DA and the main dopaminergic drugs and show the findings that support the therapeutic potential of these molecules for the treatment of neurological and non-neurological diseases considering their antioxidant and anti-inflammatory actions.

methodWe performed a review article. An exhaustive search for information was carried out in specialized databases such as PubMed, PubChem, ProQuest, EBSCO, Scopus, Science Direct, Web of Science, Bookshelf, DrugBank, Livertox, and Clinical Trials.

resultsWe showed that DA and dopaminergic drugs have emerged for the management of neuronal and nonneuronal diseases with important therapeutic potential as anti-inflammatories and antioxidants.

conclusionsDA and DA derivatives can be an attractive treatment strategy and a promising approach to slowing the progression of disorders through repositioning.

Indexed as

antiangiogenicanti-inflammatoryantinociceptiveantioxidantdopaminenonneurological disease

Identifiers

PMID36840015
PMCPMC9966027
OpenAlexW4321378021

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.